Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
13 p, 861.9 KB Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial / Dimopoulos, M.A. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens. School of Medicine) ; Špička, I. (First Department of Medicine. Department of Hematology. First Faculty of Medicine. Charles University. General Hospital in Prague) ; Quach, H. (Department of Hematology. University of Melbourne. St Vincent's Hospital) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ; Garg, M. (Hematology. Leicester Royal Infirmary. University Hospitals of Leicester NHS Trust) ; Beksac, M. (Department of Hematology. Ankara University) ; Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ; Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ; Chng, W.J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ; Leleu, X. (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ; Mateos, M.V. (Hematology. Hospital Universitario de Salamanca. University Hospital of Salamanca. Centro de Investigación del Cáncer. Instituto de Biología Molecular y Celular del Cáncer. Universitario de Salamanca Consejo Superior de Investigaciones Científicas) ; Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ; Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ; Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041  
2.
27 p, 2.4 MB Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples / Bailey, Matthew H. (Washington University School of Medicine. Department of Medicine (USA)) ; Meyerson, William U. (Yale University. Program in Computational Biology and Bioinformatics (USA)) ; Dursi, Lewis Jonathan (Ontario Institute for Cancer Research. Computational Biology Program (Canada)) ; Wang, Liang-Bo (Washington University School of Medicine. Department of Medicine (USA)) ; Dong, Guanlan (Washington University School of Medicine. Department of Medicine (USA)) ; Liang, Wen-Wei (Washington University School of Medicine. Department of Medicine(USA)) ; Weerasinghe, Amila (Washington University School of Medicine. Department of Medicine (USA)) ; Li, Shantao (Yale University. Program in Computational Biology and Bioinformatics (USA)) ; Kelso, Sean (Washington University School of Medicine. Department of Medicine (USA)) ; Saksena, Gordon (Broad Institute of MIT and Harvard) ; Ellrott, Kyle (Oregon Health and Science University. Biomedical Engineering (USA)) ; Wendl, Michael C. (Washington University School of Medicine. Department of Genetics (USA)) ; Wheeler, David A. (Baylor College of Medicine. Department of Molecular and Human Genetics (USA)) ; Getz, Gad (Broad Institute of MIT and Harvard) ; Simpson, Jared T. (Ontario Institute for Cancer Research. Computational Biology Program (Canada)) ; Gerstein, Mark B. (Yale University. Program in Computational Biology and Bioinformatics (USA)) ; Ding, Li (Washington University School of Medicine. Department of Medicine (USA))
The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. [...]
2020 - 10.1038/s41467-020-18151-y
Nature communications, Vol. 11 (September 2020) , art. 4748
2 documents
3.
12 p, 1.7 MB Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer / Kirschbrown, Whitney.P. (Clinical Pharmacology. Genentech Research and Early Development) ; Wang, B. (Clinical Pharmacology. Genentech Research and Early Development) ; Nijem, I. (Clinical Pharmacology. Genentech Research and Early Development) ; Ohtsu, A. (Department of Gastrointestinal Oncology. National Cancer Center Hospital East) ; Hoff, P.M. (Instituto do Câncer de São Paulo. Faculdade de Medicina da Universidade de São Paulo) ; Shah, M.A. (Medical Oncology/Solid Tumor Program. Sandra and Edward Meyer Cancer Center. Weill Cornell Medical College) ; Shen, L. (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing). Department of Gastrointestinal Oncology. Peking University Cancer Hospital and Institute) ; Kang, Y.K. (Department of Oncology. Asan Medical Center. University of Ulsan College of Medicine) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Girish, S. (Clinical Pharmacology. Genentech Research and Early Development) ; Garg, Amit (Clinical Pharmacology. Genentech Research and Early Development) ; Universitat Autònoma de Barcelona
Purpose: To characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the pertuzumab regimen in these patients. [...]
2019 - 10.1007/s00280-019-03871-w
Cancer Chemotherapy and Pharmacology, Vol. 84 Núm. 3 (january 2019) , p. 539-550  

Vegeu també: autors amb noms similars
1 Wang, Bei
1 Wang, Boyang
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.